CR10323A - Flavivirus pseudoinfecccioso y usos de este - Google Patents

Flavivirus pseudoinfecccioso y usos de este

Info

Publication number
CR10323A
CR10323A CR10323A CR10323A CR10323A CR 10323 A CR10323 A CR 10323A CR 10323 A CR10323 A CR 10323A CR 10323 A CR10323 A CR 10323A CR 10323 A CR10323 A CR 10323A
Authority
CR
Costa Rica
Prior art keywords
pseudoinfecccioso
flavivirus
viruses belonging
family
virology
Prior art date
Application number
CR10323A
Other languages
English (en)
Inventor
Frolov Ilya
Frolova Elena
c mason Peter
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of CR10323A publication Critical patent/CR10323A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La siguiente invencion esta relacionada a los campos de biologia molecular, virologia e inmunologia. En general, dicha invencion da a conocer la estructura de los virus pertenecientes a la familia Flaviviridae con replicacion deficiente y su uso como vacunas en la prevencion de enfermedades causadas por los virus pertenecientes a dicha familia.
CR10323A 2006-02-27 2008-09-25 Flavivirus pseudoinfecccioso y usos de este CR10323A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77718906P 2006-02-27 2006-02-27

Publications (1)

Publication Number Publication Date
CR10323A true CR10323A (es) 2009-01-29

Family

ID=38438014

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10323A CR10323A (es) 2006-02-27 2008-09-25 Flavivirus pseudoinfecccioso y usos de este

Country Status (20)

Country Link
US (2) US8252574B2 (es)
EP (1) EP1991709B1 (es)
JP (2) JP5538729B2 (es)
KR (1) KR101499750B1 (es)
CN (1) CN101454022B (es)
AP (1) AP2008004629A0 (es)
AU (1) AU2007217352B2 (es)
BR (1) BRPI0708332A2 (es)
CA (1) CA2643819C (es)
CO (1) CO6141481A2 (es)
CR (1) CR10323A (es)
EA (1) EA016490B1 (es)
HN (1) HN2008001324A (es)
IL (1) IL193522A (es)
MY (1) MY151062A (es)
NZ (1) NZ570881A (es)
SG (1) SG172642A1 (es)
UA (1) UA101597C2 (es)
WO (1) WO2007098267A2 (es)
ZA (1) ZA200807544B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103088038B (zh) * 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
EA201591888A1 (ru) 2008-03-14 2016-05-31 Санофи Пастер Байолоджикс Ко. Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
EP2435572B1 (en) 2009-05-28 2017-08-16 The United States of America, as Represented by The Secretary, Department of Health and Human Services Antigenic chimeric tick-borne encephalitis virus (tbev)/dengue virus type 4 (den4) recombinant viruses
BRPI0914507A2 (pt) * 2009-12-23 2012-04-10 Fundacao Oswaldo Cruz vacina para lentivìrus baseada em vìrus recombinante vacinal da febre amarela
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
US9402890B2 (en) * 2011-02-01 2016-08-02 Uab Research Foundation Methods and compositions for pseudoinfectious alphaviruses
US20150030565A1 (en) * 2012-01-09 2015-01-29 Sanofi Pasteur Biologics, Llc Purification of flaviviruses
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP3158060B1 (en) * 2014-06-20 2019-01-30 Université d'Aix-Marseille Method for rapid generation of an infectious rna virus
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US11149255B2 (en) * 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
US10590171B2 (en) 2016-10-28 2020-03-17 The Board Of Regents Of The University Of Texas System Exosomes and methods of making and using the same
CN110381993B (zh) * 2017-02-14 2024-03-29 得克萨斯大学体系董事会 具有3’utr缺失的活减毒寨卡病毒、含有所述病毒的疫苗及其用途
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
AU2019205330A1 (en) 2018-01-04 2020-08-27 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
AU2020417800A1 (en) 2019-12-31 2022-07-14 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
AU2021233816A1 (en) 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Coronavirus vaccine compositions and methods
AU2021320896A1 (en) 2020-08-06 2023-03-23 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2022249757A1 (ja) * 2021-05-27 2022-12-01 マイキャン・テクノロジーズ株式会社 疑似ウイルスを使用した抗体依存性感染増強反応の評価法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028487A1 (en) 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
CA2341354C (en) 1998-09-02 2009-10-20 The Government Of The United States Of America Dengue viruses that are replication defective in mosquitos for use as vaccines
EP1165842A4 (en) 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEMS FOR SCREENING LARGE QUANTITIES
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
WO2002072803A2 (en) 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
NZ533237A (en) * 2001-11-26 2005-11-25 Univ Queensland Flavivirus vaccine delivery system
AU2003258611A1 (en) 2002-08-13 2004-03-03 Akzo Nobel N.V. Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
JP4992032B2 (ja) * 2002-09-03 2012-08-08 オックスフォード バイオメディカ（ユーケー）リミテッド レトロウイルスベクター
EP2360168A1 (en) * 2002-11-08 2011-08-24 The Administrators of the Tulane Educational Fund Flavivirus fusion inhibitors
US6943015B2 (en) 2002-12-12 2005-09-13 Ilya Frolov Large scale production of packaged alphavirus replicons
WO2004072274A1 (fr) 2003-01-30 2004-08-26 Shanghai Tengen Biomedical Co., Ltd. Vaccin a base de pseudoparticules virales ayant comme support un replicon de recombinaison du virus de la dengue
JP4782668B2 (ja) * 2003-03-31 2011-09-28 エフ．ホフマン−ラ ロシュ アーゲー 日本脳炎ウィルス血清グループのメンバーを包含する一定のフラビウィルスを検出するための組成物及び方法
AU2003902842A0 (en) 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
CN103088038B (zh) 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
WO2007098267A2 (en) 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof

Also Published As

Publication number Publication date
KR20090008193A (ko) 2009-01-21
CN101454022A (zh) 2009-06-10
WO2007098267A2 (en) 2007-08-30
UA101597C2 (uk) 2013-04-25
WO2007098267A3 (en) 2008-11-20
BRPI0708332A2 (pt) 2011-05-24
EP1991709A2 (en) 2008-11-19
IL193522A (en) 2014-05-28
CO6141481A2 (es) 2010-03-19
US20130023031A1 (en) 2013-01-24
CA2643819C (en) 2018-11-27
AU2007217352A1 (en) 2007-08-30
ZA200807544B (en) 2009-11-25
US8252574B2 (en) 2012-08-28
KR101499750B1 (ko) 2015-03-06
EA016490B1 (ru) 2012-05-30
AU2007217352B2 (en) 2013-09-26
EP1991709A4 (en) 2009-10-21
MY151062A (en) 2014-03-31
CN101454022B (zh) 2013-09-04
HN2008001324A (es) 2010-10-29
US9273288B2 (en) 2016-03-01
JP2014121324A (ja) 2014-07-03
IL193522A0 (en) 2009-05-04
AP2008004629A0 (en) 2008-10-31
EA200870304A1 (ru) 2009-02-27
JP5538729B2 (ja) 2014-07-02
JP2009528032A (ja) 2009-08-06
US20090155301A1 (en) 2009-06-18
SG172642A1 (en) 2011-07-28
EP1991709B1 (en) 2017-01-25
NZ570881A (en) 2011-09-30
CA2643819A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CR10323A (es) Flavivirus pseudoinfecccioso y usos de este
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
GT200900097A (es) Inhibidores de la proteasa ns3 del hcv.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
BR112014006324B8 (pt) composição e seu uso para o tratamento de hcv
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
CL2008001983A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras.
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP13010937A (es) Compuestos antivirales
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
ECSP066792A (es) Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
DOP2006000171A (es) Inhibidores de proteasa ns3 del vhc
CR9731A (es) Inhibidores de proteasa ns3 del vhc
CL2007003685A1 (es) Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2012000147A1 (es) Compuestos derivados del acido 5-etinil-3(formilamino) tiofeno-2-carboxilico, inhibidores de los virus de la familia flaviviridae; composicion farmaceutica que comprende un compuesto; y su uso de los compuestos en la preparacion de medicamentos.
UY33445A (es) Un régimen de dosificación, métodos para tratar el virus de la hepatitis c, composición farmacéutica, compuesta, compuestos anti-hcv y kit
ECSP11011292A (es) Combinación de un inhibidor de nucleósido polimerasa con un inhibidor de proteasa macrocíclica y su uso en el tratamiento de hepatitis c, fibrosis hepática y función hepática alterada
DOP2011000366A (es) Pirazinilpirazoles
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
CL2014001651A1 (es) Glucosaminoglucano modificado químicamente que comprende cadenas de 2-20 unidades de disacáridos, el cual tiene baja actividad anticoagulante; procedimiento de preparación; composición farmacéutica; y uso para tratar distocia o fuga de proteínas de revestimientos endoteliales y epiteliales.
SV2007002309A (es) Compuestos 5-nitro-nucleosidos para tratar infecciones virales
UY28942A1 (es) Uso de imatinib para tratar trastornos hepaticos e infecciones virales
EA201001045A1 (ru) Модифицированный вирус гриппа